For the 95% of rare disease patients still without an approved treatment, FDA is working for you.
Acting Commissioner Kyle Diamantas shares how FDA is transforming rare disease drug development through the new Rare Disease Framework Initiative. Because every family deserves answers, action, and hope. fda.gov/news-events/fda-voic…
Nov 5, 2026 · 5:08 PM UTC
Thank you, @FDA_KyleD and @FDA, for recognizing the urgency facing rare disease families and advancing a framework that reflects the complexities of diseases like Huntington’s disease.
The HD community has contributed decades of natural history data, clinical trial participation, and documented risk tolerance. We welcome Priority Review of AMT-130’s BLA, but continue to advocate for CNPV consideration.
If a promising gene therapy for a fatal, relentlessly progressive disease does not warrant consideration for every appropriate expedited pathway, what does?
The success of regulatory reform will be measured not by the hope it promises, but by the patients it reaches while there is still time.
Our community has done its part. Now we look to the FDA’s leadership to ensure that urgency is translated into meaningful action.
💙💜
#HuntingtonsDisease
#RareDisease
No more lip service, please. Deramiocel from @Capricor is on your desk. Time to walk the walk or stfu about any new frameworks.
16
484
Approve #DCVAX for #GBM patients so they don’t have to travel overseas for treatment invented in the US!
braintumourresearch.org/blog…
Walk the talk and approve @Capricor deramociel product for DMD - it’s been nothing but lip service so far
8
208





















